Details.
FDA-approved intranasal esketamine treatment for adults with treatment-resistant depression or major depressive disorder with suicidality. Available in the San Francisco, San Mateo, Corte Madera, and Berkeley offices. Each session includes two hours of monitoring after the medication is delivered, and patients meet with a psychiatrist for a brief evaluation before treatment. You must not drive or operate heavy machinery until 24 hours after treatment.